Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Dec 10;2013(12):CD005425.
doi: 10.1002/14651858.CD005425.pub2.

Lipid-lowering agents for nephrotic syndrome

Xiangyu Kong  1 , Hao Yuan, Junming Fan, Zi Li, Taixiang Wu, Lanhui Jiang
Affiliations
Meta-Analysis

Lipid-lowering agents for nephrotic syndrome

Xiangyu Kong et al. Cochrane Database Syst Rev. .

Abstract

Background: Nephrotic syndrome is the collective name given to a group of symptoms that include proteinuria, lipiduria, hypoalbuminaemia, oedema, hypercholesterolaemia, elevated triglycerides, and hyperlipidaemia. Hyperlipidaemia is thought to aggravate glomerulosclerosis (hardening of blood vessels in the kidneys) and enhance progression of glomerular disease. Studies have established that reduction in total cholesterol and low density lipoprotein (LDL) cholesterol is associated with reduction in risk of cardiovascular diseases. In 2011, the European Society of Cardiology and European Atherosclerosis Society guidelines for the management of dyslipidaemia recommended use of statins as first-line agents in the management of nephrotic dyslipidaemia. However, the effectiveness and safety of statins for people with nephrotic syndrome remains uncertain. Furthermore, the efficacy of second-line lipid-lowering drugs, such as ezetimibe and nicotinic acid, has not been proven in patients with nephrotic syndrome who are unable to tolerate statin therapy.

Objectives: This review aimed to evaluate the benefits and harms of lipid-lowering agents in adults and children with nephrotic syndrome.

Search methods: We searched the Cochrane Renal Group's Specialised Register (to 18 March 2013) through contact with the Trials Search Co-ordinator using search terms relevant to this review.

Selection criteria: All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at participants with nephrotic syndrome that compared any lipid-lowering agent to placebo, no treatment or other lipid-lowering agents, given for not less than four weeks, were included.

Data collection and analysis: Two authors independently assessed study eligibility and risk of bias, and extracted data. Statistical analyses were performed using a random effects model. Dichotomous results were expressed as risk ratios (RR) with 95% confidence intervals (CI). For continuous measures mean difference (MD) was used, or the standardised mean difference (SMD) where different scales had been used.

Main results: We included five RCTs enrolling a total of 203 participants. Of these, four studies compared statins with no treatment or placebo, and one compared fibrates with placebo. We found no published studies comparing second-line agents such as ezetimibe, bile acid sequestrants, and nicotinic acid with placebo or no treatment. Our assessment of the risk of bias found that one study was judged overall to be at low risk of bias and the remaining four were judged to be at high risk of bias.Most outcomes were supported by single study data. One study reported significantly increased high density lipoprotein (HDL) cholesterol among participants in the statin arm compared with the no treatment group (MD 5.40 mg/dL, 95% CI 2.31 to 8.49). Another study reported higher serum albumin in the statin group compared to those who received no treatment (MD 0.60 g/dL, 95% CI 0.14 to 1.06). No serious adverse events, such as rhabdomyolysis, were reported, however some minor events occurred. One study reported no significant difference in the number of participants with elevated liver enzymes (RR 3.00, 95% CI 0.13 to 69.52); three studies reported liver enzymes remained within the normal range (no data provided). Four studies reported creatinine phosphokinase (CPK). One study indicated that CPK values fluctuated in both the simvastatin and placebo groups (no data provided); the remaining three studies reported CPK either stayed within the normal range (one study) or there was no significant difference between the lipid lowering agents and placebo.

Authors' conclusions: None of the included studies reported patient-centred outcomes including all-cause mortality, cardiovascular mortality, or non-fatal myocardial infarction; only single studies reported cholesterol (HDL, LDL and total cholesterol), triglycerides, serum creatinine, blood urea nitrogen, liver enzymes, and protein (serum, urine). High quality RCTs need to be conducted to assess the safety and efficacy of lipid-lowering drugs for people with nephrotic syndrome.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Study selection flow diagram
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
1.1
1.1. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 1 Total cholesterol.
1.2
1.2. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 2 LDL cholesterol.
1.3
1.3. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 3 HDL cholesterol.
1.4
1.4. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 4 Triglyceride.
1.5
1.5. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 5 Serum creatinine.
1.6
1.6. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 6 Blood urea nitrogen.
1.7
1.7. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 7 Proteinuria.
1.8
1.8. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 8 Serum albumin.
1.9
1.9. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 9 Total serum protein.
1.10
1.10. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 10 Apolipoprotein A.
1.11
1.11. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 11 Apolipoprotein B.
1.12
1.12. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 12 Elevated liver enzymes.
1.13
1.13. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 13 Alanine aminotransferase.
1.14
1.14. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 14 Aspartate aminotransferase.
1.15
1.15. Analysis
Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 15 Creatine phosphokinase.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD005425

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Buyukcelik 2002 {published data only}
    1. Buyukcelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics 2002;44(1):40‐4. [MEDLINE: ] - PubMed
Gheith 2002 {published data only}
    1. Gheith O, Saad M, Sobh M. Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258.
    1. Gheith O, Sobh M, Gazaren S, Ahmed H, Baz M. Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):100.
    1. Gheith OA, Sobh MA, Mohamed KE, Baz M, Husseini F, Gazarin SS, et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002;91(4):612‐9. [MEDLINE: ] - PubMed
Gheith 2009 {published data only}
    1. Gheith O, Sheashaa H, Abdelsalam M, Shoeir Z, Sobh M. Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine 2009;20(3):e57–e61. [MEDLINE: ] - PubMed
    1. Gheith O, Sheashaa H, Abdelsalam M, Shoeir Z, Sobh M. Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical & Experimental Nephrology 2008;12(3):189‐94. [MEDLINE: ] - PubMed
Olbricht 1999 {published data only}
    1. Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement 1999;56(Suppl 71):113‐6. [MEDLINE: ] - PubMed
Sharma 2004 {published data only}
    1. Sharma M, Nand N, Aggarwal HK, Nand D. Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine 2004;5(2):143‐6.

References to studies excluded from this review

Aguilar‐Salinas 1995 {published data only}
    1. Aguilar‐Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G. Physiologic mechanisms of action of lovastatin in nephrotic syndrome. Journal of Lipid Research 1995;36(1):188‐99. [MEDLINE: ] - PubMed
Chowdhury 2001 {published data only}
    1. Chowdhury MN, Rashid HU, Rahman H, Jahan SS, Alam MR, Iqbal M. Effect of hilsha fish oil on lipid profile in patients with nephrotic syndrome. Bangladesh Renal Journal 2001;20(1):14‐9. [EMBASE: 2002291093]
Cruzado 2011 {published data only}
    1. Cruzado JM, Poveda R, Ibernon M, Díaz M, Fulladosa X, Carrera M, et al. Low‐dose sirolimus combined with angiotensin‐converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrology Dialysis Transplantation 2011;26(11):3596‐602. [MEDLINE: ] - PubMed
D'Amico 1991 {published data only}
    1. D'Amico G, Gentile MG. Effect of dietary manipulation on the lipid abnormalities and urinary protein loss in nephrotic patients. Mineral & Electrolyte Metabolism 1992;18(2‐5):203‐6. [MEDLINE: ] - PubMed
    1. D'Amico G, Gentile MG. Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients. Kidney International ‐ Supplement 1991;39(Suppl 31):65‐9. [MEDLINE: ] - PubMed
    1. D'Amico G, Remuzzi G, Maschio G, Gentile MG, Gotti E, Oldrizzi L, et al. Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome. Clinical Nephrology 1991;35(6):237‐42. [MEDLINE: ] - PubMed
    1. Gentile MG, D'Amico G, Redaelli L, Gotti E, Perticucci E, Biase V, et al. Dietary treatment of hyperlipidaemia in patients with nephrotic syndrome. [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo (Japan). 1990:121A.
De Zeeuw 1995 {published data only}
    1. Dullaart RP, Gansevoort RT, Sluiter WJ, de Zeeuw D, de Jong PE. The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidaemia in response to antiproteinuric treatment. Metabolism 1996;45(6):723‐30. [MEDLINE: ] - PubMed
    1. Dullaart RP, Gansevoort RT, Sluiter WJ, de Zeeuw D, de Jong PE. The serum lathosterol/cholesterol ratio, an index of cholesterol synthesis, is not elevated in human nephrotic syndrome and is not associated with improvement of hyperlipidaemia in response to antiproteinuric treatment [abstract]. Journal of the American Society of Nephrology 1995;6(3):385. - PubMed
Garcia de la Puent 2009 {published data only}
    1. García‐de‐la‐Puente S, Arredondo‐García JL, Gutierrez‐Castrellon P, Bojorquez‐Ochoa A, Maya ER, Perez‐Martínez M. Efficacy of simvastatin in children with hyperlipidaemia secondary to kidney disorders. Pediatric Nephrology 2009;24(6):1205‐10. [MEDLINE: ] - PubMed
Golper 1989 {published data only}
    1. Golper TA, Illingworth DR, Morris CD, Bennett WM. Lovastatin in the treatment of multifactorial hyperlipidaemia associated with proteinuria. American Journal of Kidney Diseases 1989;13(4):312‐20. [MEDLINE: ] - PubMed
Groggel 1989 {published data only}
    1. Groggel GC, Cheung AK, Ellis‐Benigni K, Wilson DE. Treatment of nephrotic hyperlipoproteinaemia with gemfibrozil. Kidney International 1989;36(2):266‐71. [MEDLINE: ] - PubMed
Kaliev 2001 {published data only}
    1. Kaliev RR, Sydykova AT, Mirrakhimov EM. Effect of lovastatin, exogenous hypobaric hypoxia and its combination on hyperlipidaemia in patients with nephrotic glomerulo‐nephritis [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:151.
Rabelink 1988 {published data only}
    1. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988;2(8624):1335‐8. [MEDLINE: ] - PubMed
Rayner 1996 {published data only}
    1. Rayner BL, Byrne MJ, Zyl Smit R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clinical Nephrology 1996;46(4):219‐24. [MEDLINE: ] - PubMed
Resh 2011 {published data only}
    1. Resh M, Mahmoodi BK, Navis GJ, Veeger NJ, Lijfering WM. Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thrombosis Research 2011;127(5):395‐9. [MEDLINE: ] - PubMed
Spitalewitz 1993 {published data only}
    1. Spitalewitz S, Porush JG, Cattran D, Wright N. Treatment of hyperlipidaemia in the nephrotic syndrome: the effects of pravastatin therapy. American Journal of Kidney Diseases 1993;22(1):143‐50. [MEDLINE: ] - PubMed
Thomas 1993 {published data only}
    1. Thomas ME, Harris KPG, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International 1993;44(5):1124‐9. [MEDLINE: ] - PubMed
Toto 2000 {published data only}
    1. Toto RD, Grundy SM, Vega GL. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolaemia and combined hyperlipidaemia secondary to the nephrotic syndrome. American Journal of Nephrology 2000;20(1):12‐7. [MEDLINE: ] - PubMed
    1. Toto RD, Vea GL, Grundy SM. Pravastatin improves hypercholesterolemia of the nephrotic syndrome by enhancing clearance of apolipoprotein B [abstract]. Journal of the American Society of Nephrology 1992;3(3):321.

References to ongoing studies

ISRCTN06912061 {published data only}
    1. Querfeld U. Prospective, multicenter, double‐blind, randomised, cross‐over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidaemia in children with persisting proteinuria. controlled‐trials.com/ISRCTN06912061 (accessed 9 October 2013).

Additional references

4S Group 1994
    1. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383‐9. [MEDLINE: ] - PubMed
Appel 1985
    1. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. New England Journal of Medicine 1985;312(24):1544‐8. [MEDLINE: ] - PubMed
Appel 1990
    1. Appel GB, Appel AS. Lipid‐lowering agents in proteinuric diseases. American Journal of Nephrology 1990;10 Suppl 1:110‐5. [MEDLINE: ] - PubMed
ATP II 1993
    1. Anonymous. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269(23):3015‐23. [MEDLINE: ] - PubMed
Bagga 1995
    1. Bagga A, Sharma A, Srivastava RN. Inefficacy of pefloxacin in steroid‐responsive nephrotic syndrome. Pediatric Nephrology 1995;9(6):793‐4. [MEDLINE: ] - PubMed
Chan 2005
    1. Chan CM. Hyperlipidaemia in chronic kidney disease. Annals of the Academy of Medicine, Singapore 2005;34(1):31‐5. [MEDLINE: ] - PubMed
Chapman 2010
    1. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 2010;126(3):314‐45. [MEDLINE: ] - PubMed
Culleton 1999
    1. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community‐based cohort with mild renal insufficiency. Kidney International 1999;56(6):2214‐9. [MEDLINE: ] - PubMed
De Backer 2003
    1. De Backer G, Ambrosioni E, Borch‐Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention & Rehabilitation 2003;10(4):S1‐S10. [MEDLINE: ] - PubMed
ESC/EAS 2011
    1. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011;32(1):1769‐818. [MEDLINE: ] - PubMed
Ezetimibe PI 2002
    1. Zetia (ezetimibe) product information, 2002. Merck/Schering‐Plough Pharmaceuticals. Available from http://www.merck.com/product/usa/pi_circulars/z/zetia/zetia_pi.pdf.
Falk 2001
    1. Falk RJ, Jennette C, Nachman PH. Primary glomerular disease ‐ nephrotic syndrome. In: Brenner BM, Levine SA editor(s). Brenner & Rector's the Kidney. 6th Edition. Philadelphia: Saunders, 2001:1266‐83. [ISBN: 0721691749]
Gordon 1995
    1. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM editor(s). Lowering cholesterol in high‐risk individuals and populations. Vol. 24, New York: M Dekker, 1995. [ISBN: 0824794125]
Hayslett 1969
    1. Hayslett JP, Krassner LS, Bensch KG, Kashgarian M, Epstein FH. Progression of "lipoid nephrosis" to renal insufficiency. New England Journal of Medicine 1969;281(4):181‐7. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins J, Altman D, Sterne J (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
K/DOQI 2003
    1. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. American Journal of Kidney Diseases 2003;41(4 Suppl 3):S1‐S91. [MEDLINE: ] - PubMed
Kamanna 2008
    1. Kamanna VS, Kashyap ML. Mechanism of action of niacin. American Journal of Cardiology 2008;101(8A):20B‐26B. [PUBMED: 18375237] - PubMed
Kasiske 1998
    1. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. American Journal of Kidney Diseases 1998;32(5 Suppl 3):S142‐56. [MEDLINE: ] - PubMed
Keane 1994
    1. Keane WF. Lipids and the kidney. Kidney International 1994;46(3):910‐20. [MEDLINE: ] - PubMed
Krishna Das 2002
    1. Krishna Das KV. Nephrology ‐ nephrotic syndrome. Textbook of medicine. Fourth. Vol. 2, Jaypee Brothers Medical Publishers Pty. Ltd, 2002:893‐8.
Law 1994
    1. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 1994;308(6925):367‐72. [MEDLINE: ] - PMC - PubMed
Ordonez 1993
    1. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney International 1993;44(3):638‐42. [MEDLINE: ] - PubMed
Sacks 1996
    1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine 1996;335(14):1001‐9. [MEDLINE: ] - PubMed
Shepherd 1995
    1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995;333(20):1301‐7. [MEDLINE: ] - PubMed
Valeri 1986
    1. Valeri A, Gelfand J, Blum C, Appel GB. Treatment of hyperlipidaemia of the nephrotic syndrome: A controlled trial. American Journal of Kidney Diseases 1986;8(6):388‐96. [MEDLINE: ] - PubMed
Wheeler 1994
    1. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. American Journal of Kidney Diseases 1994;23(3):331‐46. [MEDLINE: ] - PubMed

References to other published versions of this review

Fan 2005
    1. Fan J, Li Z, Wu T, Chen H. Lipid‐lowering agents for nephrotic syndrome. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005425] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources